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Abstract 
The purpose of this analysis is to examine specific segments of healthcare policy and practice, applying 
various ethical perspectives. We examine the economic and political influences that surround ethical 
behavior in health services, as well as how practitioners, patients, and families respond and act as a result of 
such influences. We then delve into the fundamental principles that guide ethical behavior by medical 
practitioners, including the Hippocratic Oath and vows of medical professionalism. Further, we analyze 
disparities in healthcare provisions based on gender, race, and ethnicity. Ethical theory is weaved into each 
of these sections, as the philosophical and ethical writings of prominent scholars illuminate how the 
conditions of contemporary healthcare administration are affected by the injustices and political influences 
that pervade the entire health services industry. 
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  Introduction 
 The purpose of this analysis is to examine specific segments of healthcare policy and 
practice, applying various ethical perspectives. First, we provide a general overview of the 
common ethical issues that confront the healthcare industry. More specifically, we examine the 
economic and political influences that surround ethical behavior in health services, as well as 
how practitioners, patients, and families respond and act as a result of such influences. We then 
delve into the fundamental principles that guide ethical behavior by medical practitioners, 
including the Hippocratic Oath and vows of medical professionalism. To this end, we cover 
elements of doctor-patient communication, clinical decisions regarding administration of care 
and prescription medication, and the issues of direct-to-consumer drug advertising (DTCA). 
Moreover, we elucidate these ethical issues by providing bona fide examples of such situations 
and the ramifications they carry. Because of the vast divisions in healthcare services and 
differences in care across geographical and socioeconomic levels, we analyze disparities in 
healthcare provisions based on gender, race, and ethnicity. Such disparities represent a 
significant challenge to the ethical pursuit of equal and just healthcare administration for all 
peoples. Ethical theory is weaved into each of these sections, as the philosophical and ethical 
writings of prominent scholars illuminate how the conditions of contemporary healthcare 
administration are affected by the injustices and political influences that pervade the entire health 
services industry.  
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Literature Review 
General Overview on Ethics in the Healthcare Industry 
The study of ethics in the healthcare industry often focuses on issues that arise in medical 
and clinical settings, including: medical research, patient autonomy and care, patient health care, 
and professional relationships (Werhane & Rorty, 2000). The general consensus regarding the 
foremost professional purposes of the healthcare industry is that it provides services to society 
requiring medical attention, to secures and maintains the overall health of those who are healthy, 
and protects important healthcare values necessary to set the standard for the profession 
(Emanuel, 2000). Healthcare professions and professionals inherently expect out of their 
associates the traits of trustworthiness, accountability, personal integrity, and expertise 
(Emanuel, 2000). In addition, Emanuel (2000) stresses that the elements that make healthcare 
professions unique is the fact that the self-interests of medical professionals are subordinated by 
the very calling of their profession. In fact, in the healthcare industry, the need to provide 
professional services takes precedence over the interests of the care being provided to the 
organizations themselves. Emanuel (2000) identifies eight professional practice areas where 
healthcare professionals have the responsibility to hold expertise: 1) decision making, 2) 
fiduciary obligations, 3) confidentiality, 4) obligations consequential to patient vulnerability, 5) 
personal standards, 6) equity, 7) cultural representation, and 8) procedures for resolving 
dilemmas. 
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Political and Economic Responsibilities of the Healthcare Industry 
The healthcare industry has political and economic responsibilities, too (Emanuel, 2000).  
The political purpose refers to the fact that citizens (both patients and professionals) are 
intrinsically entitled to express their own voices on how medical care and treatment are 
administered: in a fair, just, respectable, and personable manner. Also, there is an economic 
purpose to the healthcare industry; healthcare services are governed and piloted by the market, 
economy, and financial forces in the surroundings. Patients essentially represent the consumers, 
whereas the healthcare professionals or practitioners signify the purveyors. Yet, as Emanuel 
(2000) emphasizes, the purpose of health care in general claims precedence over the other two 
purposes. One main reason is that the political purpose is important in outlining the procedures 
through which the healthcare industry functions. Unless efforts devoted to this purpose are 
strictly aligned with professional objectives, these efforts can inadvertently transform into 
promotional methods of self-interest. The economic function is necessary for financial feasibility 
and affordability. Unless these protocols are guided to fall in line with the interests of both 
patients and the public health sector, circumstances can deviate from the intended path and 
become more specific toward self-promotion. As Emanuel (2000) later concludes, the political 
and economic purposes should stand in second place to the professional purpose. In doing so, a 
combination of mission statements, by-laws, and other similar structures is conveyed. 
Ethical Issues Confronting Practitioners, Patients, and Families 
According to Aulisio, Arnold, and Youngner (2000), healthcare providers, patients, and 
families are routinely confronted with ethical questions such as: competence, confidentiality, 
informed consent, medical futility, patient autonomy, resource allocation, rights of conscience, 
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and surrogate decision making. Such questions revolve around values generally accepted by 
societies. As history typically reveals, laws and policies reflect the values practiced by those 
societies. Laws often dictate decisions and ethics based on commonly accepted values. Policies, 
however, direct ethically-relevant matters based on internal and external environmental factors.   
Ethics represents a political and social issue, as well as one that is philosophical and 
conceptual. Healthcare professionals need to critically examine these ethical conditions to 
genuinely comprehend the ethical ambiguities that exist within their professions. If healthcare 
organizations sense the need to promote the basic purposes for which they stand, then their very 
structure should be founded on such definitive ethical values. In short, the organizational 
structures should be consistent with the ethical values as set forth by the professional healthcare 
system. 
Accountability in the Healthcare Field 
A fundamental ethical concept in healthcare settings is accountability. According to 
Emanuel (2000), accountability refers to a rendering of account for responsibilities entailed by 
the job assumed. The purpose of this accountability helps identify rationalizations, feedback, and 
amendments to the appropriate parties. Accountability inherently implies reciprocity between 
those who are accountable and those to whom accountability is held. Accountability is a two-
way relationship; that is, not a single entity is without some sort of accountability. Each entity 
must strive to hold others accountable for their actions. It is important to recognize that 
accountability is not intended to be solely applied for punitive reasons; such accountability also 
serves as an inherent constituent in the occupation itself. In healthcare settings, such reciprocal 
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accountability can be found in relationships between physicians, patients, nurses, pharmacists, 
clinics, hospitals, insurance companies, government, and the general public (Emanuel, 2000). 
Examples of Accountability Concerns 
Accountability can present mixed controversial issues and matters of questionability. A 
prime anecdote is the infamous case of the anencephalic infant: Baby K (Mason, Laurie, & Aziz, 
2006).  Anencephalic babies possess a brain stem (i.e., the Pons and Medulla) yet lack essential 
neurological structures – the cerebrum or cerebellum. Figure 1 comparatively depicts a normal 
infant brain (left) and an abnormal, anencephalic infant brain (right). 
 
Figure 1: Normal Brain and Anencephalic Brain (Mason, Laurie, & Aziz, 2006) 
 
Anencephalic babies are capable of breathing and heart rhythms, yet they lack important 
sensory components: vision, hearing, and touch. They are physically alive when at birth, but their 
post-partum lifespan is short-lived. In the anecdote of Baby K, this child was born in Virginia in 
1992.  At the insistence of the mother, Baby K received a series of aggressive life-sustaining 
treatments until the baby died at the age of 2. As a matter of financial importance, the treatment 
undertaken to prolong the life of this deformed infant cost the private insurer and Medicaid over 
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$500,000USD. Under such circumstances, the notion of accountability enters into the ethical 
equation. Hospitals are professionally and legally obligated to place the well-being of their 
patients at the forefront, especially in emergency situations. Yet, common sense dictates that if 
the healthcare industry and insurance companies need to avoid significant financial losses (which 
tend to render increased premiums across the general population), there should be a restraint on 
such an unrestrained approach to healthcare delivery (Paris & Post, 2000). In the context of 
healthcare costs being as enormous as they currently are – not only are professional standards 
and guidelines ethically considered, but so are fiscal issues.  
Shortcomings of Ethical Theories in the Healthcare Industry 
Jaeger (2001) asserts that available ethical theories fall short in explaining the complex 
problems that exist in the healthcare industry. Jaeger (2001) defines moral sensitivity as 
“openness to the differences that can exist between people involved in a particular decision-
making situation, and it depends on both an understanding and respect for the complexity of 
meaningfulness in human life” (p. 139). Moral sensitivity goes beyond understanding what 
others are feeling or experiencing. Being ethical requires that people comprehend and appreciate 
that they may not share the same value systems as others. As such, Jaeger (2001) recommends 
that healthcare facilities should include administrative systems that create environments that 
motivate workers to be both ethical and accountable.  
 
 
 
 
 
ETHICAL HEALTH CARE        8 
 
The Hippocratic Oath: The Ultimate Ethical Foundation  
for Physician Practice and Patient Care 
 
Hippocrates: The Father of Western Medicine 
 Hippocrates was, and still remains, a renowned physician, a pioneer in Greek medicine, 
and to many, the “father of western medicine”, who lived from 460 to 370 B.C. (Goldberg, 
2006). Hippocrates developed the first scientific medical paradigm, led the medical field’s 
independence from religion and philosophical speculation, and devised an original code 
regarding medical ethics. Although the common method of healing the ill was to deliver them to 
a sacred temple for supplication to Aesculapius – the god of medicine (Stern, 2005; Sykiotis, 
Kalliolias, & Papavassiliou, 2005) – Hippocrates conceded that pathology generated from natural 
sources. Hippocrates believed that the human body, with its inherent immune system, could 
recover on its own, leading to healing and restoration. His direct observations of symptoms and 
the development of disease enabled him to describe many of today’s commonly known maladies: 
pneumonia, arthritis, malaria, etc.. Hippocrates exhorted like-minded physicians to strive to 
ensure the restoration of the sick, and that physicians should be honorable in their practice 
(O’Neil, 2006).  
Original and Modern Version of the Hippocratic Oath 
 The Hippocratic Oath is a sacred vow that has been both historically and traditionally 
pledged by physicians with respect to their ethical practice of medicine. Because physicians have 
sworn to this oath for more than two millennia, this “word of honor” has been asserted to have 
been created by Hippocrates himself; hence the name (Goldberg, 2006; Stern, 2005). The 
Hippocratic Oath was initially intended to prohibit physicians from participating in abortions and 
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surgical procedures in which knowledge of the surgical practice itself was unfamiliar. In 
contemporary society, physicians pledge to a reformed version of the oath as a necessary and 
legal part of graduating from medical school (O’Neil, 2006). Essentially, the oath stipulates that 
novice physicians swear to strictly practice and uphold professional ethical standards. The most 
prominent element to this oath, in today’s practice, is to avoid committing harm to patients.   
It is crucial that the entire Hippocratic Oath, in its modern form, be iterated so that a clear 
understanding of its nature, seriousness, and the ethical implications it carries are fully 
recognized. As such, the Hippocratic Oath is as follows: 
“I will respect the hard-won scientific gains of those physicians in whose steps I walk, 
and gladly share such knowledge as is mine with those who are to follow. I will apply, for the 
benefit of the sick, all measures [that] are required, avoiding those twin traps of overtreatment 
and therapeutic nihilism. I will remember that there is art to medicine as well as science, and that 
warmth, sympathy, and understanding may outweigh the surgeon’s knife or the chemist’s drug. I 
will not be ashamed to say “I know not,” nor will I fail to call in my colleagues when the skills of 
another are needed for a patient’s recovery. I will respect the privacy of my patients, for their 
problems are not disclosed to me that the world may know. Most especially must I tread with 
care in matters of life and death. If it is given me to save a life, all thanks. But it may also be 
within my power to take a life; this awesome responsibility must be faced with great humbleness 
and awareness of my own frailty. Above all, I must not play at God. I will remember that I do 
not treat a fever chart, a cancerous growth, but a sick human being, whose illness may affect the 
person’s family and economic stability. My responsibility includes these related problems, if I 
am to care adequately for the sick. I will prevent disease whenever I can, for prevention is 
preferable to cure. I will remember that I remain a member of society, with special obligations to 
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all my fellow human beings, those sound of mind and body as well as the infirm. If I do not 
violate this oath, may I enjoy life and art, respected while I live and remembered with affection 
thereafter. May I always act so as to preserve the finest traditions of my calling and may I long 
experience the joy of healing those who seek my help (Lasagna, 1964).” 
Surprisingly, the Hippocratic Oath has diminished in popularity among medical 
professions in the last several decades. As a result, in 1999, American and European medical 
societies formed a special committee: the Medical Professionalism Project. Too, this committee 
devised a renewed oath: the Charter on Medical Professionalism (O’Neil, 2006). According to 
Stern (2005), the professional and ethical responsibilities in this reformed oath include: 1) 
professional competence, 2) honesty with patients, 3) patient confidentiality, 4) maintaining 
appropriate relations with patients, 5) improving quality of care and access to care, 6) just 
distribution of finite resources, 7) scientific knowledge, 8) maintaining trust by managing 
conflicts of interest, and 9) professional responsibilities. These ethical obligations represent the 
core values of professional medical practice.  
Ethical Dilemmas Regarding Doctor-Patient Communication 
The delicate relationships that doctors and patients share are based on a mutually 
agreeable understanding regarding their purpose(s) within the clinical interaction. Essentially, the 
purpose of this type of healthcare interaction is to achieve an effective and realistic medical 
result – to manage and ensure the welfare of the patient. Keenly associated with reaching this 
outcome within the doctor-patient relationship is the requirement of key social and ethical 
elements, particularly benevolence, honesty, confidentiality, and trust (Breen et al., 2009). These 
fundamental traits within the doctor-patient interaction are both of moral and legal priority and 
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relevance. Further, the provision of an appropriate “standard of care” – that is, a form and level 
of care that aims to avoid or minimize patient harm – is both mandated and expected by our 
society’s commonly held moral convictions and governmental laws that serve to perpetuate a 
sense of trust within general healthcare practice. Thus, the very nature of the doctor-patient 
relationship must be clearly secured within tight ethical boundaries. 
Clinical Decisions Regarding the Administration of Prescription Medications 
Of the numerous ethical issues that surround doctor-patient relationships, the clinical 
communications regarding decisions over pharmaceutical prescriptions represent one such 
ethical concern (Petersen, 2008).  Over the past century, there have been significant changes, not 
to mention varying expectations, in the relationships that physicians and their patients share.  The 
traditional, paternalistic model of clinical decision-making, in which doctors dominate and 
preempt medical decisions on behalf of their patients, has become a decreasingly observed and 
acceptable practice across the country. The role of the patient within the clinical interaction has 
become increasingly emphasized in recent years, most notably through the adoption of a strategy 
known as “patient-centered” (or patient-centric) care (Breen et al., 2009; Stewart et al., 1995). 
Patient-centric care involves the physician employing active listening skills as a means to 
encourage patient expression regarding their own, personal agendas. In addition, this form of 
care seeks to understand patients’ perspectives and expectations, and aims to create a cooperative 
doctor-patient interaction in which to find common ground regarding clinical and case 
management (Stevenson, Barry, Britten, Barber, & Bradley, 2000). Therefore, patients no longer 
act as blind consumers, as this patient-centric practice enables them to become increasingly 
active in clinical participation. 
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Ethical Concerns Surrounding Direct-to-Consumer Drug Advertising 
 There is a myriad of ethical breaches and dilemmas in doctor-patient communication 
regarding the decisions surrounding prescription drug administration (Petersen, 2008). 
Interrelated ethical deficiencies are complicated even further by various intrinsic and extrinsic 
factors. Diverse ethical implications in doctor-patient communication cannot be clearly defined, 
and this communication should be accompanied by honesty, confidentiality, genuine necessity, 
and trust in terms of both morality and legality. Breen et al. (2009) emphasized that the existence 
of credibility and comfort in doctor-patient communication can improve quality of care. This 
credibility must be driven by ethical responsibility. According to Breen et al. (2009), there is a 
strong, positive correlation between increased, quality communication and improved feelings of 
satisfaction and trust between medical practitioners and patients. This finding represents a key 
lesson, one that propagates the message that doctor-patient relationships can be enhanced via 
mutual trust. This kind of reciprocally beneficial relationship can also positively affect care and 
treatment quality.   
Patients’ Involvements in Prescription Drug Advertising 
Patients’ clinical participation has also been accelerated by the rampant phenomenon 
known as direct-to-consumer drug advertising (DTCA), primarily spawned by the 
pharmaceutical industry (Loe, 2006; Petersen, 2008). Drug advertising creates a pervasive 
dissemination of education and information for consumers regarding new products, prompting 
and enabling many consumers to seek out such medication through their physicians. Since 
pharmaceutical companies have started mass advertisement of prescription drugs, both directly to 
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consumers and physicians (Petersen, 2008), understanding the clinical, psychological, and ethical 
impacts of drug advertising on physicians and consumers becomes critical. 
DTCA has increased rapidly in the United States over last decade in particular (Loe, 
2006; Mintzes et al., 2003; Petersen, 2008). Too, prescription pharmaceuticals are being ever 
more advertised via a variety of media outlets – television, magazines, and multimedia. Such 
advertising is a powerful tool, strategically designed to create widespread demand as a financial 
method to maximize profits (Petersen, 2008; Practice Advisory, 2001). DTCA clearly serves as 
an educational tool as well, providing both medical practitioners and patients with drug product 
information. 
Primary Effects of DTCA 
Despite the many benefits of DTCA, the costs are staggering. DTCA will inevitably drain 
healthcare dollars, dramatically increase unnecessary prescribing, and strain doctor-patient 
relationships (Hoffman & Wilkes, 1999). The overall influences involved in DTCA have only 
been critically studied for just under a decade (Bell, Kravitz, & Wilkes, 1999; Petersen, 2008). 
To deal with these issues, one prudent suggestion would be to ethically approach and improve 
doctor-patient communication. Put differently, if an open, affable, and two-sided relationship can 
be clinically developed in the practitioner-patient relationship, this interactive style should lead 
to more appropriate and necessary decisions in the prescription of pharmaceuticals. This 
approach should help to control and regulate healthcare expenses in general. 
According to the Practice Advisory (2001), neurologists in particular may be solicited by 
pharmaceutical or medical device companies to participate in DTCA since general practitioners 
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are the targets of aggressive DTCA marketing. A keynote committee, formed by the Practice 
Advisory (2001), functions under the following ethical tenets:  
1) Patient education materials produced by pharmaceutical and medical device  
companies may provide useful information but should also serve the purpose of  
advertising and should therefore be regarded as DTCA.  
2)  Mass marketing through DTCA may not promote a drug or device to an individual for  
                 whom it is unsuitable.  
3)  Participation in DTCA may have an unfavorable effect on a neurologist’s professional  
                 reputation and trusted relationship with patients.  
4)  The relationship between neurologists and industry merits further analysis and 
                 improvement.  
5) Public information about advances in therapy should be effectively conveyed from     
    reliable, impartial sources. 
Ethical Anecdotes of DTCA Administrations 
Since the emergence of DTCA, more people are now requesting prescription drugs from 
their physicians, leading to, in many cases, physician compliance with those patient 
pharmaceutical requests (Kopp & Bang, 2000; Petersen, 2008). A serious issue with this 
situation is that misleading drug advertisements can lead to negative and dangerous 
consequences. For example, many prescription analgesics (pain relievers) are chemically derived 
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and produced from opium, the same substance that produces heroin’s notoriously euphoric 
effects (Petersen, 2008). Drug-seeking patients may successfully pretend or feign illness in order 
to obtain these drugs. Similar patients may also seek to maintain a continuous supply of these 
drugs from their prescribing physicians. Then, as this drug consumption pattern becomes 
crystallized, the patient can be led to iatrogenic addiction.  
Even if the pain and physical complaints are legitimate and verifiable (such as an illness 
related to the nervous system), repeated administration of narcotic medications for pain 
management can contribute to severe addiction problems and potential overdose. Fentanyl, one 
such powerful opiate for the relief of chronic pain conditions, has led to serious overdoses and 
cases of death (Borland, Jacobs, King, & O’Brien, 2007). The FDA has required Fentanyl patch 
producers to make special medication instructions that will accompany every box, articulating 
proper use of this drug. Figure 2 illustrates Fentanyl and its warnings issues by the FDA.  
 
Figure 2: Fentanyl and FDA Warning (Borland, Jacobs, King, & O’Brien, 2007) 
 
These kinds of examples are common occurrences in clinical practice, and represent one major 
way in which the ethical treatment of patients is crucial for the overall reputation and perception 
of healthcare delivery. 
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Viagra is another well-known drug that epitomizes a clash in DTCA and ethics (Loe, 
2006). Viagra is clinically indicated for the use and treatment of male erectile dysfunction or 
impotence. Figure 3 illustrates a common DTCA of Viagra and the hyperbolized benefits of this 
medication. 
 
Figure 3: DTCA of Viagra (Loe, 2006) 
 
One major side effect of this medication is pulmonary arterial hypertension (PAH), a 
potentially life-threatening condition (Loe, 2006). Although this kind of pharmaceutical product 
can negatively affect physiological functioning, some consumers believe that the positive effects 
on their psychological health outweigh the risks to their physical health. The ethical 
circumstances surrounding the costs and benefits of this medication need to be carefully 
weighed. For instance, there are numerous ethical discourses concerning Viagra: 1) Is sex 
medically necessary or elective? and 2) Is there a physical or psychological defense that ethically 
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merits insurance companies to cover Viagra? Under these conditions, how physicians and 
patients ethically negotiate these issues represent ethics in health communication. 
The History of Pharmaceutical Advertising 
Regulation 
 Pharmaceutical advertising regulation originated in 1938 with the passage of the Federal 
Food, Drug and Cosmetic Act and the establishment of the Food and Drug Administration, or the 
FDA (Gellad & Lyles, 2007). In 1962, the act was amended to require that medications be 
proven both safe and efficacious before being advertised to the public (Gellad & Lyles, 2007).   
 According to Shaw (2008), mass media DTCA did not exist before 1980, because 
pharmaceutical manufacturers aimed their marketing efforts at physicians, relying on the strength 
of the traditional doctor-patient relationship to sell their products. An “about-face” in this 
marketing philosophy occurred in the early 1980s, when Boots Pharmaceuticals aired the first 
DTCA for the anti-arthritis drug: Rufen (Shaw, 2008). Subsequent DTCA for Pneumovax, a 
pneumonia vaccine, reflected Merck’s recognition that patients were taking a more proactive role 
in their care and the prescriptions their physicians were writing for them. These and other 
advertisements started to raise concerns about the ramifications of DTCA. Consequently, the 
FDA called for a voluntary moratorium on DTCA in order to craft a more explicit policy (Shaw, 
2008). In 1985, however, the moratorium ended with revised guidelines that called for DTCA to 
adhere to the same rules that govern pharmaceutical advertising to physicians (Gellad & Lyles, 
2007).  Gellad and Lyles (2007) noted that the FDA’s decision limited DTCA because the drug 
manufacturers believed the brief summary requirement (i.e., a summary of the product label 
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including risk-related information in all promotional material) would dull any promotional effect 
of advertisements on consumers. 
 In 1997, the FDA reformed these policies again and allowed DTCA to appear on 
television (Donahue, Cevasco, & Rosenthal, 2007). New policies allowed for the removal of the 
brief summary requirement and permitted manufacturers to tell customers that there were 
alternative resources – such as web sites and toll-free telephone numbers – for obtaining that 
information.  This policy became known as the adequate provision requirement (Gellad & Lyles, 
2007).  Another major change enabled drug manufacturers to use the drug’s brand name and 
benefits in the same advertisement(s).  Further, in 2004, the FDA stated that print advertisements 
were no longer required to list full prescribing information (Shaw, 2008).      
DTCA Growth: 1997-2007 
 Following the FDA’s policy change in 1997, DTCA exploded in popularity and visibility 
over the next decade.  Pharmaceutical promotion grew at an average annual rate of 10.6% from 
$11.4 billion in 1996 to $29.9 billion in 2005 (Donahue, Cevasco, & Rosenthal, 2007).  
According to Donahue, Cevasco, and Rosenthal (2007), spending on DTCA increased 330% 
from 1996 to 2005, representing 54.4% in the total industry spending in 2005, encompassing 20 
individual drugs.  Gellad and Lyles (2007) also reported that, during a one-week period in 
Atlanta, three television networks broadcasted 907 advertisements for over-the-counter 
medications and 428 advertisements for prescription medications.   
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The Fiscal Benefits of DTCA for Pharmaceutical Companies 
Pharmaceutical company’s DTCA campaigns also paid off handsomely, with a major 
return on their investments. Boden and Diamond (2008) reported that for more than 90% of the 
brand name medications, 70% reaped returns in excess of $1.50 for every $1.00 invested. Also, 
35% generated returns in excess of $2.50 for every $1.00 invested. Table 1 illustrates these 
financial gains of the top 10 prescription drug sales in the United States between 2003 and 2007. 
Table 1: 2007 Top Pharmaceutical Products by U.S. Sales (Boden & Diamond, 2008) 
Rank Product
2007 Total 
Dollars (U.S. 
Billions)
2006 Total 
Dollars (U.S. 
Billions)
2005 Total 
Dollars (U.S. 
Billions)
2004 Total 
Dollars (U.S. 
Billions)
2003 Total 
Dollars (U.S. 
Billions)
1 Lipitor 8.1 8.7 8.4 7.8 6.8
2 Nexium 5.5 5.2 4.4 3.8 3.1
3 Advair Diskus 4.3 4.0 3.6 3.0 2.3
4 Plavix 3.9 3.0 3.5 3.1 2.3
5 Seroquel 3.5 3.0 2.6 2.1 1.6
6 Singulair 3.4 3.0 2.5 2.2 1.8
7 Enbrel 3.4 3.1 2.8 2.0 1.4
8 Prevacid 3.4 3.6 3.8 3.9 4.1
9 Aranesp 3.3 4.0 2.8 1.9 1.0
10 Epogen 3.1 3.2 3.0 3.0 3.1
All 286.5 276.1 253.9 239.9 219.6
Source: IMS National Sales Perspective
 
The pharmaceutical companies’ blockbuster DTCA budgets and drug sales, as well as the 
general effects of the advertisements on consumers, have not gone unnoticed.  In 2007, Senators 
Ted Kennedy and Mike Enzi introduced Senate Bill S. 1082, the Food and Drug Administration 
Revitalization Act, mandating moratoriums on new prescription drugs, requiring pre-clearance of 
DTCA, and requiring certain language is included in these advertisements (Shaw, 2008).   
The Food and Drug Administration Amendments Act (FDAAA) of 2007 became legally 
enacted in September 2007, but pharmaceutical advertising moratoriums were removed from the 
bill following “freedom of commercial speech” objections from the American Advertising 
Federation (Shaw, 2008).  On May 20, 2008, the Pharmaceutical Research and Manufacturers of 
America issued a media release addressing the value of DTCA.  The release reiterated PHRMA’s 
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commitment to an “honest and open dialogue” with Congress and other stakeholders concerning 
the main benefits of DTCA.  The statement from PHRMA (2008) essentially conveyed that 
increasing awareness of treatment options via DTCA advertising not only informs and educates 
patients potentially suffering from illness(es), but it also benefits the overall U.S.-based 
healthcare system by influencing patients to pursue medical attention that may assist them in the 
management of their conditions and in avoiding unnecessary hospital visits or procedures. 
Direct-to-Consumer Drug Advertising Strategies 
The Pharmaceutical Research and Manufacturers of America (2008), also known as 
PHRMA, defines direct-to-consumer drug advertising (DTCA) with respect to print and 
broadcast mediums.  Each of these mediums involves unique implications. A print advertisement 
– whether appearing in direct mail, newspaper, or magazine publications – is paid for by a given 
company and is then directed to consumers for the purpose of presenting information about the 
company’s medicine and excludes any mention of sponsorship activities (PHRMA, 2008). 
Broadcast advertisement is bought by a given company for appearance on broadcast or cable 
television that conveys information (excluding sponsorship activities) about one or more of the 
company’s medicines (PHRMA, 2008).  As of November 22, 2007, DTCA expanded to include 
medical devises, with the broadcasting of a DTCA advertisement during a professional football 
game that presented information about Cypher, a drug-eluding coronary stent used in 
percutaneous transluminal coronary angioplasty (Boden & Diamond, 2008). 
The Ethics of DTCA: Helpful or Harmful? 
 Attitudes and opinions regarding the helpfulness or harm caused by DTCA vary – not 
surprisingly – depending upon one’s position within or outside the pharmaceutical, advertising, 
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medical, or regulatory industries. Findlay (2002) asserts that DTCA advertisements are either 
creating 1) a considerable, new demand for prescription medications, and/or 2) physician visits 
for drug requests, which represent a minor component of such visits. Further, Findlay (2002) 
concludes that DTCA has stimulated doctor visits and an increased awareness of new 
medications and medical conditions so that patients can acquire needed medications.  As an 
“ethical” case in point, what research fails to provide is whether such doctor visits or drug 
requests – prompted by DTCA – are appropriate and necessary. 
 Almasi, Stafford, Kravitz, and Mansfield (2006) claim that DTCA aims to persuade 
rather than to inform, and that the information it does provide is flawed and incomplete. Boden 
and Diamond (2008) point out that two FDA telephone surveys conducted in 1999 and 2002 
found that DTCA prompted many patients to seek out new information for available medical 
treatments and to ask more informed questions of their medical providers. However, Boden and 
Diamond (2008) temper this information-seeking benefit with concerns that DTCA television 
advertisements inevitably fail to completely reveal the benefits and risks that must be provided in 
print advertising, resulting in a diminished standard of disclosure (and one that is of significant 
concern to physician opponents of DTCA, not to mention congressional, supervisory 
committees). 
 Hollon (2005) reports that more than 80% of physicians believe DTCA does not provide 
fair and balanced information. What remains uncertain is whether DTCA helps doctors and their 
patients achieve the goal of improved patient health through shared decision making (Hollon, 
2005).  In a similar vein, Hollon (2005) revealed the reports of a randomized controlled trial 
involving specific drug requests from “standardized patients” and found that, while DTCA may 
guard against insufficient or incomplete treatment, DTCA simultaneously undermines optimal 
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prescribing, thereby stimulating the overtreatment for lesser conditions, and probably rendering 
harm in cases where the risk of therapy is not understood or is substantial. 
 Not surprisingly, the advertising industry’s perspective on DTCA helpfulness and 
effectiveness differs with those of the medical community and members of Congress. Hoek and 
Gendall (2002) conclude that criticisms of DTCA lack any empirical foundation and the benefits 
of DTCA outweigh the “largely unproven disadvantages” associated with it.  Mehta and Purvis 
(2003) surveyed 1,475 women and explored their attitudes and responses to print DTCA. Their 
results showed that women generally value DTCA, which seems to encourage respondents to ask 
their doctors about what they read (Mehta & Purvis, 2003).   
Huh and Becker (2005) examined the FDA’s 1999 National Survey Data and identified 
that DTCA exposure was strongly correlated to drug information seeking, thinking about 
communication with doctors, and actual communication with doctors.  The study also revealed 
that other factors – such as prescription drug use, health conditions, demographic variables and 
control over health care – only indirectly affect key behavioral variables via DTCA exposure 
(Huh & Becker, 2005). 
 In a recent consumer survey (Snyder, 2008), 34% of adults aged 18 to 26 said they trust 
pharmaceutical companies less than they did previously. In response, the CEO of the American 
Advertising Federation (AAF) urged the advertising and pharmaceutical industries to regain 
public trust via optimized ethical advertising, an approach that provides honest, forthright, and 
ethical medical information to consumers who rely upon it. What can be deduced from these 
various propositions and statements by published authors is that DTCA is neither good nor bad. 
What needs to be done at this point is that policymakers must decide how to maximize DTCA 
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benefits, and at the same time minimize its risks, within the American free enterprise system 
(Almasi, Stafford, Kravitz, & Mansfield, 2006).   
An Ethical Dilemma Regarding Healthcare Disparities 
Racial and ethnic health disparities are one of the most challenging ethical issues 
currently facing the healthcare system. In a country founded on principles of equality of 
opportunity, the fact that race and ethnicity are associated with poor health gives rise to the 
question of whether or not the American healthcare system is unjust in the equitable distribution 
of healthcare services. Since the early 1940s, the United States has recognized that minorities 
have faced different health outcomes than their non-minority counterparts (Myrdal, 1996). In 
fact, Mays, Cochran, and Barnes (2007) reported that the health outcomes of minorities in 1990 
were comparable to those of the health outcomes of the non-minorities in the 1920s, highlighting 
the fact that the health outcomes of African-American males living in an inner-city region of the 
United States were worse than those of males living in Bangladesh, one of the world’s most 
impoverished countries (Mays, Cochran, & Barnes, 2007).  Since that time, voluminous reports 
demonstrating disparities in rates of morbidity, mortality, disease, and injury have shown that the 
health outcomes of racial and ethnic minorities are consistently worse than those of the non-
minority groups in several major categories (Smedley, Stith, & Nelson, 2003).   
In 2003, the U.S. Congress was presented with a comprehensive report by the Institute of 
Medicine that provided empirical evidence that racial and ethnic minorities faced unequal 
treatment on several levels of the healthcare system, unequal access to healthcare services, and a 
lower quality of healthcare services, resulting in poorer health outcomes.  Such health disparities 
were found in a wide range of diseases, treatments, services, recommended therapies, and 
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outcomes.  Additionally, studies have found that racial and ethnic health disparities persist 
regardless of income level, education level, or insurance status (Kressin & Peterson, 2001; 
Krieger, 2005; Nazroo & Williams, 2006; Smedley, Stith, & Nelson, 2003).  One prominent 
example is found in cases of infant mortality, a key indicator of a community’s overall health 
status. The African-American infant mortality rate is over twice the rate for white infants. Even 
worse, the infant mortality rate for white women without even a high school diploma is better 
than the infant mortality rate for college-educated, African-American women (Nazroo & 
Williams, 2006). In light of the fact that technological, medical, and societal advancement have 
generally improved the health of the overall population – yet still fails to improve in the areas of 
racial and ethnic minorities – how does the healthcare system justify the continuation of the 
current structure and how do healthcare providers ensure that the system in which they operate 
and their manner of practice are just?  These questions remain prominent ethical considerations 
and dilemmas for the both healthcare system and the general public. 
Fundamental Ethical Considerations in United States History 
The U.S. constitution posits that, as a nation – that is, as a free and independent country –
the United States of America will seek to establish justice for all people. However, given the 
current state of health for minorities in the U.S., there is an assertion that the U.S. has fallen short 
in achieving the goal of justice in the equitable distribution of healthcare services. Over the 
years, there have been formidable debates over whether or not health care is a guaranteed right, 
as well as the extent of the role of government in the distribution of healthcare services (Daniels, 
1985). Health and health services for the American worker are extremely important as individual 
and societal productivity is based upon the ability and capacity of the American worker.  
Individuals of ill or poor health are afforded less opportunity for social and economic prosperity, 
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which, in effect, reduces their quality of life. Thus, a social justice issue arises as equality of 
opportunity is denied when a fair and equitable healthcare system is not established for the 
provision of health care to those with the greatest need(s) (Smedley, Stith, & Nelson, 2003).   
At the heart of the ethical dilemma is the fact that minorities often receive a lower quality 
of healthcare delivery than their non-minority counterparts, regardless of socioeconomic status. 
This phenomenon supports the idea that disparities are more about race and ethnicity than class 
or other statuses. The current system links affordable healthcare insurance with employment 
despite the fact that racial and ethnic minorities are more likely to have lower educational 
attainment, lower paying jobs, or are unemployed (Nazroo & Williams, 2006). Some scholars 
argue that the failure of the system to provide quality care to minorities, the omission of 
healthcare services by providers, and the resulting inferior health status of minorities serves as 
evidence of institutionalized discriminatory practices, representing an ethical violation of 
individual civil rights and a lack of fair and just treatment (Randall, 2002; Smedley, Stith, & 
Nelson, 2003).   
Governmental Ethics in Health Services 
As our first ethical consideration, we rely on John Rawls’ (1971) “theory of justice”. We 
use this theory to determine the role of government in healthcare distribution to American 
citizens. From an egalitarian perspective, all people should be treated as equals, and all social 
primary goods – including liberty, opportunity, income, and wealth – should be distributed 
equally, save an unequal distribution of goods is advantageous to the person(s) in the least 
favorable position (Rawls, 1971). In other words, there is an underlying assumption that all 
individuals will have access to opportunity through the provision of education and resources to 
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improve their individual economic status. Daniels (1985), a contemporary ethical philosopher, 
asserts that inequalities are unjust because they demonstrate America’s inability to evenly 
distribute controllable resources, failing in their effort to protect equality of opportunity for racial 
and ethnic minorities. Since everyone is fundamentally entitled to the broadest array of basic 
goods and services, and because health represents a state of soundness in mental, physical, and 
social capacities, it is inevitably considered a basic provision. It serves as the foundation from 
which every activity generated by the individual occurs. As a result, health care represents a core 
ingredient in an individual’s overall ability to pursue economic goals. A true egalitarian position 
requires equality in access to care, treatment, and services for all people, particularly those who 
are disproportionately burdened with poor health (e.g., racial minorities) (Smedley, Stith, & 
Nelson, 2003).  
Healthcare Practitioners’ Ethical Considerations 
 Although the overall structure of the healthcare system is important from a contextual 
perspective, the ethical practices of individual providers represent a critical element of health 
outcomes in individual patients. Currently, providers adhere to the ethical standards prescribed in 
the American Medical Association’s (AMA) code of conduct.  In establishing these standards, 
the AMA sought to offer an ethical framework that prioritizes the provider’s responsibility to the 
patient first, followed by the greater society, other health professionals, and finally to the 
individual provider (AMA, 2006).  For the purposes of this discussion, we focus on the AMA’s 
ethical principles that state that a physician shall be dedicated to delivering competent medical 
care with compassion and esteem for human dignity and human rights (AMA, 2006). The 
principle prioritizes the need for physicians to offer services with respect for human dignity and 
human rights. If human dignity refers to a state worthy of respect, and if human rights are those 
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basic rights guaranteed by the constitution, it would appear that providers would be bound by 
their ethical principles to provide quality care to every patient they serve.   
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